Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipelineJul 30Quarterly updateAlnylam Pharmaceuticals